Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 26, 2021 16:00 ET | Source: Arcellx, Inc.

Arcellx Appoints Rami Elghandour as Chairman and Chief Executive Officer

GAITHERSBURG, Md., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced the...
December 07, 2020 10:00 ET | Source: Arcellx, Inc.

Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma

- Company announces initial results in first-in-human trial utilizing novel synthetic binding domain - - 6/6 (100%) overall response rate (ORR) per International Myeloma Working Group (IMWG)...
November 05, 2020 09:30 ET | Source: Arcellx, Inc.

Arcellx Announces Clinical Data to be Presented at the 62nd American Society of Hematology (ASH) Annual Meeting

Presentation to include clinical data from Arcellx’s ongoing Phase 1 study of CART-ddBCMA, a genetically engineered cell therapy utilizing the company’s novel synthetic binding domain for the...
October 02, 2020 07:08 ET | Source: Arcellx, Inc.

Arcellx to Present at Jefferies Virtual Cell Therapy Summit

GAITHERSBURG, Md., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Arcellx today announced that David Hilbert, Chief Executive Officer, will present at the following upcoming investor conference. Presentation...
August 24, 2020 07:00 ET | Source: Arcellx, Inc.

Arcellx Announces EvansMDS Grant Awarded for Collaboration with Johns Hopkins and University of Colorado Researchers to Support Development of Arcellx ARC-sparX Platform Candidate ACLX-002

- Edward P. Evans Foundation funding initiative to support efforts toward clinical development of Arcellx candidate cell therapy in the treatment of myelodysplastic syndromes - GAITHERSBURG, Md.,...
June 22, 2020 09:00 ET | Source: Arcellx, Inc.

Arcellx Presents Preclinical Data for ARC-sparX Platform Technology in Targeting CD123-Positive AML Tumors

GAITHERSBURG, Md., June 22, 2020 (GLOBE NEWSWIRE) -- Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with...
June 02, 2020 07:00 ET | Source: Arcellx, Inc.

Arcellx to Present at Jefferies Virtual Healthcare Conference

GAITHERSBURG, Md., June 02, 2020 (GLOBE NEWSWIRE) -- Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with...
May 19, 2020 14:23 ET | Source: Arcellx, Inc.

Arcellx to Present at the UBS Virtual Global Healthcare Conference

GAITHERSBURG, Md., May 19, 2020 (GLOBE NEWSWIRE) -- Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with...
May 13, 2020 17:01 ET | Source: Arcellx, Inc.

Arcellx to Present Preclinical Data of its Novel ARC-sparX Platform Technology in Targeting HER2+ Solid Tumors at the 2020 American Society of Clinical Oncology Virtual Annual Meeting

GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with...
April 29, 2020 13:24 ET | Source: Arcellx, Inc.

Arcellx to Present Preclinical Efficacy Data of the ARC-sparX Platform Technology at the 2020 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

GAITHERSBURG, Md., April 29, 2020 (GLOBE NEWSWIRE) -- Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients...